Looking Forward to AAO: Advances in Retinal Disease and Gene Therapy

Overview

The upcoming American Academy of Ophthalmology (AAO) annual meeting will feature a comprehensive retina subspecialty program highlighting advances in inherited retinal diseases (IRD), gene therapy, and retinal disorders. Recent global meetings like Euretina have showcased innovations in retinal management, with ongoing clinical trials and new therapies such as encapsulated cell therapy for macular telangiectasia type 2.

Background

Inherited retinal diseases represent a rapidly evolving field with significant research focused on genetic underpinnings and novel treatments. Gene therapy is emerging as a promising approach for conditions like retinitis pigmentosa, Stargardt disease, and Leber congenital amaurosis. Additionally, retinal complications of systemic diseases such as sickle cell disease require specialized management. Annual meetings like AAO and Euretina provide critical platforms for education, collaboration, and dissemination of cutting-edge retinal research.

Data Highlights

The article does not provide specific numerical data but highlights ongoing clinical trials and newly approved therapies, including revakinagene taroretcel-lwey (Encelto) for macular telangiectasia type 2.

Key Findings

• The AAO retina subspecialty day offers a 2-day educational program with lectures, panels, and debates on medical and surgical retina.
• Inherited retinal diseases are a focus area with multiple clinical trials investigating gene therapies for retinitis pigmentosa, Stargardt disease, and Leber congenital amaurosis.
• Sickle cell retinopathy manifestations and management strategies are reviewed, emphasizing systemic disease impact on retinal health.
• Revakinagene taroretcel-lwey (Encelto) is an FDA-approved encapsulated cell therapy delivering ciliary neurotrophic factor to slow photoreceptor loss in macular telangiectasia type 2.
• Global retina meetings like Euretina attract thousands of specialists, fostering international collaboration and knowledge exchange.
• Retinal Physician will provide video interviews and highlights from AAO, enhancing access to the latest retinal research and clinical insights.

Clinical Implications

Clinicians should stay informed about emerging gene therapies and novel treatment modalities for inherited retinal diseases to optimize patient care. Awareness of systemic disease impacts on the retina, such as sickle cell retinopathy, remains essential. Participation in professional meetings and utilization of educational resources can enhance clinical skills and knowledge in this rapidly advancing field.

Conclusion

The AAO annual meeting and other global retina congresses continue to be vital venues for advancing retinal disease management through education and collaboration. Ongoing innovations in gene therapy and cell-based treatments hold promise for improving outcomes in inherited and degenerative retinal disorders.

References

1. Do DV, Retinal Physician, 2023 -- Looking Forward to AAO